PubRank

Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 25128013)

Published in Clin Lymphoma Myeloma Leuk on July 14, 2014

Authors

Jonathan D Cicci1, Larry Buie2, Jill Bates2, Hank van Deventer3

Author Affiliations

1: Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC. Electronic address: jcicci@unch.unc.edu.
2: Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC.
3: Division of Hematology Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.

Articles citing this ↘

Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90

Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag (2015) 0.85

Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol (2015) 0.79